EU approves Sanofi/Regeneron’s Zaltrap for mCRC

By KEVIN GROGAN Another day and another approval in Europe for Sanofi, this time for its colorectal cancer drug Zaltrap. The European Commission has granted marketing authorisation ...

Just 4 of 37 Massachusetts compounding pharmacies passed surprise health inspections

By Kay Lazar and Chelsea Conaboy Surprise state inspections at 37 specialty pharmacies in Massachusetts show that only four have been fully complying with industry safety standards, ...

Not Working Out So Well At Merck?

By Derek Lowe Here’s a rather grim analysis from the Associated Press of Merck’s (MRK) current status. The company’s stock was recently downgraded by two analysts ...

Allergan Seeks to Sell Lap-Band and Obesity Unit By June

By Michelle Fay Cortez Allergan Inc. (AGN), the maker of the Botox wrinkle treatment, said it’s committed to selling the company’s obesity-treatment unit in the first half of 2013 ...

Covidien Announces Continued Relationship with NYSE Euronext

By Covidien Covidien (COV), a leading global provider of healthcare products, today announced that Mallinckrodt plc intends to apply to list its ordinary shares on the New York Stock ...

Zimmer Told to Pay Stryker $70 Million in Patent Case

By Susan Decker Zimmer Holdings Inc. was told to pay $70 million to Stryker Corp. for infringing patents related to a device that removes damaged tissue and cleans bones during ...

J&J ‘Informational’ Faxes Are Not Junk: Judge

By Ed Silverman Doctor beware: some of those faxes arriving from drugmakers may be perfectly legitimate and not the sort of unwanted missive that have prompted some physicians to file ...

Where, Oh Where, Has All The Pharma Talent Gone?

By Ed Silverman File this under ‘sad irony.’ Now that the pharmaceutical industry has tossed thousands of people overboard during the last decade – an estimated 150,000 or so ...

Hemispherx’s Ampligen odyssey ends with (another) FDA rejection

By John Carroll Five years after filing for an approval of the chronic fatigue syndrome drug Ampligen, the FDA has spurned the application again, asking for additional information ...

Merck Serono nabs an option on late-stage MS therapeutic vax

By John Carroll Close to two years after Merck KGaA was forced to concede the embarrassing collapse of its oral multiple sclerosis program for cladribine, its Serono unit has picked ...

GSK boosts trials disclosures sans support from pharma peers

By Ryan McBride GlaxoSmithKline ($GSK) stands virtually alone among drugmakers in its drive to open its vaults of clinical trials data and provide new access to nitty-gritty details ...

Left on FDA ‘hold,’ Idenix hangs up on once-hot hep C drugs

By John Carroll For the past few weeks Idenix ($IDIX) has been methodically moving away from its once-promising hepatitis C drugs, put on clinical hold by a jittery FDA in the wake ...
Page 3 of 5512345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS